Biotrendz Medicament Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 84.94%
(FY 2023)
- Ebitda 88.36%
(FY 2023)
- Net Worth -486.20%
(FY 2023)
- Total Assets -0.10%
(FY 2023)
About Biotrendz Medicament
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Keshav Kumar, Vijay Uppal, and Anand Uppal serve as directors at the Company.
- CIN/LLPIN
U24304CH2020PTC042885
- Company No.
042885
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biotrendz Medicament?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Keshav Kumar  | Director | 24-Jan-2020 | Current |
| Vijay Uppal | Director | 24-Jan-2020 | Current |
| Anand Uppal | Director | 24-Jan-2020 | Current |
Financial Performance of Biotrendz Medicament.
Biotrendz Medicament Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 84.94% increase in profit. The company's net worth observed a substantial decline by a decrease of 486.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biotrendz Medicament?
Unlock access to Biotrendz Medicament's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Vadsp Pharma Care Private LimitedActive 36 years 7 monthsVijay Uppal and Anand Uppal are mutual person
Chemzin Graphics Private LimitedActive 4 years 4 monthsVijay Uppal and Anand Uppal are mutual person
- Chemzin Biotox Research Institute Private LimitedActive 1 year 3 months
Vijay Uppal and Anand Uppal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biotrendz Medicament?
Unlock and access historical data on people associated with Biotrendz Medicament, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biotrendz Medicament, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biotrendz Medicament's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
